Corporate Banner
Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Diagnoplex S.A. Closes a Financing Round Led by Debiopharm Group™

Published: Friday, June 07, 2013
Last Updated: Friday, June 07, 2013
Bookmark and Share
Diagnoplex secures 1.3 million Swiss francs from financing round.

Diagnoplex SA and Debiopharm Diagnostics SA have announced that Diagnoplex has secured 1.3 million Swiss francs from a financing round led by Debiopharm.

Other investors include Neomed and Initiative Capital Romandie.

The funds will be used to help Diagnoplex obtain CE marking (European Conformity) for Colox, a non-invasive blood-based test for the early detection of colon cancer.

The company also wishes to prepare a comparative clinical trial with the screening test that should allow for patient reimbursement.

Early detection of colon cancer and subsequent intervention by colonoscopy will have an important impact on the prevention of this cancer that has a high mortality rate. Indeed, it has been demonstrated that survival rates improve up to 90% when colorectal cancer is detected early.

Colorectal cancer is the third most common cancer in men (663 000 cases, 10.0% of the total) and the second in women (571 000 cases, 9.4% of the total) worldwide.

“We are very pleased to announce the renewal commitment of Debiopharm, who led this round. This financing will allow Diagnoplex to continue its development and to progressing in establishing a collaboration for the commercialization of its diagnostic test,” commented Stavros Therianos, Ph.D., Chief Executive Officer and founder of Diagnoplex.

“The early screening of colon cancer is key. It is tomorrow’s personalized medicine. We are proud to contribute to the progress of such an entrepreneurial and innovative company such as Diagnoplex,” said Thierry Mauvernay, Delegate of the Board of Debiopharm Group.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Debiopharm Acquires FibroTrap Sample Processing Technology from Spinomix
FibroTrap improves sensitivity and shortens time taken from sample collection to results.
Saturday, June 20, 2015
Immunexpress Closes $6M Financing Round led by Debiopharm
Funding to advance development of the Immunexpress SeptiCyte® technology.
Thursday, March 06, 2014
Debiopharm to Acquire Affinium’s Antibiotic Clinical Assets and Platform
Company acquire clinical and preclinical assets to identify and develop targeted antibiotics.
Wednesday, February 12, 2014
Debiopharm, Immunexpress and Biocartis Announce Collaboration
Collaboration to advance development of SeptiCyte® Triage for managing sepsis.
Wednesday, December 26, 2012
Augurix Receives the 2011 ‘Debiopharm /Valais Award’
Company receives award for its point-of-care diagnostic test for the early detection of Celiac disease.
Wednesday, November 16, 2011
Debiopharm Group™ Starts Phase I Clinical Trial with Debio 0932
A targeted small molecule inhibitor of heat shock protein 90 for cancer treatment.
Wednesday, April 28, 2010
Debiopharm Group™ and Biocartis embark on a Partnership Aiming at Enhancing Personalized Medicine
- Debiopharm Group™ , a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target unmet medical needs, and which has embarked in the field of companion diagnostics with a view to progressing in the area of personalized medicine, today announced the signature of an investment agreement with Biocartis.
Thursday, April 08, 2010
Debiopharm Group™ Grants Licence for Development, Manufacture and Commercialization of Debio 025
The product is currently in phase 2b clinical development for the treatment of hepatitis C.
Wednesday, February 10, 2010
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
'Fountain of Youth' Protein Points to Possible Human Health Benefit
Patients with higher blood levels of growth factor have lower risk of cardiovascular problems.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Imaging Software Could Speed Breast Cancer Diagnosis
Technology could improve access to diagnostic services in developing countries.
Data Mining DNA For Polycystic Ovary Syndrome Genes
A new Northwestern Medicine genome-wide association study of PCOS – the first of its kind to focus on women of European ancestry – has provided important new insights into the underlying biology of the disorder.
Algorithm Interprets Breathing Difficulties to Aid in Medical Care
Researchers from North Carolina State University have developed an efficient algorithm that can interpret the wheezing of patients with breathing difficulties to give medical providers information about what’s happening in the lungs.
Researchers Develop qPCR Prognosis Test for NSCLC Patients
A nine-gene molecular prognostic index (MPI) for patients with early-stage non-small cell lung cancer (NSCLC) was able to provide accurate survival stratification and could potentially inform the use of adjuvant therapy in patients struggling with the disease.
Genetic Test Could Improve Blood Cancer Treatment
Testing for genetic risk factors could improve treatment for myeloma – a cancer of the blood and bone marrow – by helping doctors identify patients at risk of developing more aggressive disease.
PTR-MS Breath Test Shows Potential for Detecting Liver Disease
Researchers at the University of Birmingham have published results that suggest a non-invasive breath test for liver disease using an IONICON PTR-MS.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!